Ultra-low dose of intravitreal bevacizumab in retinopathy of prematurity

2017 ◽  
Vol 187 (2) ◽  
pp. 417-421 ◽  
Author(s):  
A. Şahin ◽  
Z. Gürsel-Özkurt ◽  
M. Şahin ◽  
F. M. Türkcü ◽  
A. Yıldırım ◽  
...  
Keyword(s):  
Retinopathy Of Prematurity ◽  
Low Dose ◽  
Intravitreal Bevacizumab

Ultra-Low Dose of Intravitreal Bevacizumab in the Treatment of Retinopathy of Prematurity

2015 ◽  
Author(s):  
Alan J. Connor ◽  
Vasileios T. Papastavrou ◽  
Roxane J. Hillier ◽  
Ayad Shafiq
Keyword(s):  
Retinopathy Of Prematurity ◽  
Low Dose ◽  
Intravitreal Bevacizumab

scholarly journals Effects of Low Dose of Intravitreal Bevacizumab in Retinopathy of Prematurity

2014 ◽  
Vol 26 (1) ◽  
pp. 95-99
Author(s):  
Yuta SAITO ◽  
Isamu ITO ◽  
Toshihiko UEDA ◽  
Michiko MATSUBARA ◽  
Haruo TAKAHASHI
Keyword(s):  
Retinopathy Of Prematurity ◽  
Low Dose ◽  
Intravitreal Bevacizumab

Contralateral effect of systemic absorption of low dose bevacizumab (Avastin) after unilateral intravitreal injection in severe retinopathy of prematurity (ROP)

2020 ◽  
Vol 13 (3) ◽  
pp. e232359
Author(s):  
Ayad Shafiq ◽  
Roxane Hillier ◽  
Richard Hearn
Keyword(s):  
Side Effects ◽  
Retinopathy Of Prematurity ◽  
Low Dose ◽  
Intravitreal Bevacizumab ◽  
Premature Baby ◽  
Systemic Absorption ◽  
Medium Term ◽  
Contralateral Effect ◽  
Development Assessment

An extremely premature baby boy born at 23 weeks’ gestational age was treated with unilateral low dose of 0.16 mg/0.025 mL intravitreal bevacizumab in the left eye for aggressive retinopathy of prematurity (ROP). He developed photographically documented changes in his contralateral right eye on imaging 5 days later. Second eye treatment was at 12 days. He has development assessment and ophthalmic review beyond age 2, which is normal. Systemic absorption of the drug caused an end organ effect to slow down and reverse ROP in his untreated right eye. Both eyes vascularised fully. His normal Bayley III developmental score at age 2 is uncommon for a 23-week gestation baby. Even at a low dose, bevacizumab has the potential for end organ effect on the second eye, and therefore other organs. In this case, there are no medium-term measurable neurodevelopmental side-effects. We suggest longer term follow-up is required before excluding unwanted side-effects.

Ultra-low-dose intravitreal bevacizumab for the treatment of retinopathy of prematurity: a case series

2017 ◽  
Vol 102 (2) ◽  
pp. 260-264 ◽  
Author(s):  
Roxane J Hillier ◽  
Alan J Connor ◽  
Ayad E Shafiq
Keyword(s):  
Retinopathy Of Prematurity ◽  
Low Dose ◽  
Standard Dose ◽  
Treatment Success ◽  
Case Series ◽  
Intravitreal Bevacizumab ◽  
Optimal Dose ◽  
Additional Treatment ◽  
Complete Regression ◽  
North East

BackgroundIntravitreal bevacizumab (IVB) has emerged as an effective treatment modality for the management of retinopathy of prematurity (ROP) where the disease is severe and posterior. Despite evidence of systemic vascular endothelial growth factor suppression and concerns about how this might affect the developing neonate, the optimal dose is unknown to date. We report our experience of using ultra-low-dose (0.16 mg) IVB, one-quarter of the ‘standard’ dose that has widely been reported in the treatment of ROP.MethodsA retrospective observational case series of consecutive infants who underwent ultra-low-dose IVB injection for the management of ROP at a regional neonatal intensive care unit in the North East of England, between November 2013 and August 2016.Results29 eyes of 15 infants underwent IVB injection. We defined ‘treatment success’ as complete regression of retinopathy and vascularisation into (or laser ablation of) zone 3. Primary success (in response to IVB 0.16 mg alone) was observed in 23/29 eyes (79.3%). Secondary success (where additional treatment was required) was observed in 27/29 eyes (93.1%). One infant died of respiratory disease during follow-up. Retreatment occurred in 6/29 eyes (20.6%). Retreatments occurred at a mean of 9.8 weeks after initial IVB (range 6–15) and at a mean of 44 weeks postmenstrual age (range 40–50).Conclusion0.16 mg IVB is effective in the treatment of severe and posterior ROP, with no adverse ocular outcomes occurring in our series.

Intravitreal bevacizumab monotherapy for retinopathy of prematurity

2013 ◽  
Vol 55 (5) ◽  
pp. 599-603 ◽  
Author(s):  
Alparslan Şahin ◽  
Muhammed Şahin ◽  
Abdullah Kürşat Cingü ◽  
Yasin Çınar ◽  
Fatih Mehmet Türkcü ◽  
...  
Keyword(s):  
Retinopathy Of Prematurity ◽  
Intravitreal Bevacizumab
Sign in / Sign up

Export Citation Format

Share Document